TR201907804T4 - Apaf-1 inhibitör bileşikleri. - Google Patents
Apaf-1 inhibitör bileşikleri. Download PDFInfo
- Publication number
- TR201907804T4 TR201907804T4 TR2019/07804T TR201907804T TR201907804T4 TR 201907804 T4 TR201907804 T4 TR 201907804T4 TR 2019/07804 T TR2019/07804 T TR 2019/07804T TR 201907804 T TR201907804 T TR 201907804T TR 201907804 T4 TR201907804 T4 TR 201907804T4
- Authority
- TR
- Turkey
- Prior art keywords
- apaf
- inhibitor compounds
- piperazinedione
- prophylaxis
- apoptosis
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 abstract 1
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical class O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Abstract
Formül (I)'e sahip 2,5-piperazinedionun türevleri, apoptotik peptidaz aktive edici faktör 1 (Apaf-1) inhibitörleridir, bu nedenle apoptozdaki artışla ilişkili bir patolojik ve/veya fizyolojik durumun profilaksisi ve/veya tedavisi için aktif farmasötik bileşenler olarak faydalıdırlar.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200901757 | 2009-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201907804T4 true TR201907804T4 (tr) | 2019-06-21 |
Family
ID=43529761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/07804T TR201907804T4 (tr) | 2009-07-30 | 2010-07-29 | Apaf-1 inhibitör bileşikleri. |
Country Status (15)
Country | Link |
---|---|
US (1) | US9040701B2 (tr) |
EP (1) | EP2460798B1 (tr) |
JP (1) | JP5694320B2 (tr) |
KR (1) | KR101786761B1 (tr) |
CN (1) | CN102574818B (tr) |
AU (1) | AU2010277505B2 (tr) |
BR (1) | BR112012002134B8 (tr) |
CA (1) | CA2769408C (tr) |
EA (1) | EA021838B1 (tr) |
ES (1) | ES2727711T3 (tr) |
IN (1) | IN2012DN01378A (tr) |
MX (1) | MX2012001339A (tr) |
NZ (1) | NZ598125A (tr) |
TR (1) | TR201907804T4 (tr) |
WO (1) | WO2011012746A2 (tr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1912679A4 (en) | 2005-06-15 | 2009-07-29 | Massachusetts Inst Technology | AMINOUS LIPIDS AND ITS USES |
MX353900B (es) | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
EP3318248B1 (en) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
EP2609135A4 (en) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | POLY (BETA-AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF |
US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
NZ719345A (en) | 2011-06-08 | 2023-03-31 | Translate Bio Inc | Lipid nanoparticle compositions and methods for mrna delivery |
MX363734B (es) * | 2011-10-27 | 2019-03-29 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco. |
WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
EP2859102A4 (en) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF |
ES2443538B1 (es) * | 2012-07-19 | 2014-11-26 | Consejo Superior De Investigaciones Cientificas (Csic) | Compuestos beta-lactámicos inhibidores de APAF1 |
WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
WO2014152966A1 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Methods for purification of messenger rna |
PL2968586T3 (pl) | 2013-03-14 | 2019-01-31 | Translate Bio, Inc. | Kompozycje mrna cftr i związne z nimi sposoby i zastosowania |
US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
CN112656954A (zh) | 2013-10-22 | 2021-04-16 | 夏尔人类遗传性治疗公司 | 用于递送信使rna的脂质制剂 |
WO2015061500A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
CN105658242A (zh) | 2013-10-22 | 2016-06-08 | 夏尔人类遗传性治疗公司 | 用于苯丙酮尿症的mrna疗法 |
WO2015164773A1 (en) | 2014-04-25 | 2015-10-29 | Shire Human Genetic Therapies, Inc. | Methods for purification of messenger rna |
WO2015184256A2 (en) | 2014-05-30 | 2015-12-03 | Shire Human Genetic Therapies, Inc. | Biodegradable lipids for delivery of nucleic acids |
EP3160959B1 (en) | 2014-06-24 | 2023-08-30 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
FI3310764T3 (fi) | 2015-06-19 | 2023-07-18 | Massachusetts Inst Technology | Alkenyylillä substituoidut 2,5-piperatsiinidionit ja niiden käyttö koostumuksissa agenssin kuljettamiseksi subjektille tai soluun |
MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
MA49138A (fr) | 2017-05-16 | 2020-03-25 | Translate Bio Inc | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
CN112702983B (zh) | 2018-04-19 | 2023-06-30 | 斯皮拉尔诊疗有限公司 | 内耳药物递送装置和使用方法 |
CN112930396B (zh) | 2018-08-24 | 2024-05-24 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
US10561736B1 (en) | 2019-01-09 | 2020-02-18 | Spiral Therapeutics, Inc. | Apoptosis inhibitor formulations for prevention of hearing loss |
AU2020229314A1 (en) | 2019-02-25 | 2021-09-16 | Spiral Therapeutics, Inc. | Intratympanic injector devices and needles for delivery of drugs and methods of use |
EP4137131A1 (en) * | 2021-08-17 | 2023-02-22 | Centre National de la Recherche Scientifique (CNRS) | Novel serotonin analogues and their uses for treating iron-associated disorders |
CN115124449B (zh) * | 2022-05-24 | 2024-02-02 | 上海英诺富成生物科技有限公司 | 一种吲哚化合物及制备方法与应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3560503A (en) * | 1968-09-18 | 1971-02-02 | Council Scient Ind Res | Di-lower alkyl-substituted octahydropyrazinopyrimidinones |
GB1284582A (en) | 1969-11-10 | 1972-08-09 | Council Scient Ind Res | Substituted piperazinopyrimidinones |
JPH04234375A (ja) | 1990-12-27 | 1992-08-24 | Ajinomoto Co Inc | 新規2,5−ジオキソピペラジン化合物及びその製造法 |
WO1992019595A1 (en) * | 1991-05-07 | 1992-11-12 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
JPH05117246A (ja) | 1991-10-23 | 1993-05-14 | Ajinomoto Co Inc | 新規2,5−ジオキソピペラジン化合物とその製造法及びα−L−アスパルチル−L−フエニルアラニンメチルエステル誘導体の製造法 |
WO1996000391A1 (en) * | 1994-06-23 | 1996-01-04 | Affymax Technologies N.V. | Methods for the synthesis of diketopiperazines |
DE60201415T2 (de) * | 2001-01-19 | 2006-02-09 | Pharmacopeia, Inc. | Bisarylderivate mit fsh rezeptor modulierender aktivität |
JP4674317B2 (ja) | 2002-10-02 | 2011-04-20 | ディエムアイ アクイジション コーポレイション | 疾病の判定および監視 |
JP4447557B2 (ja) | 2003-11-28 | 2010-04-07 | 協和発酵バイオ株式会社 | ジペプチドの製造法 |
ES2296484B1 (es) * | 2005-11-23 | 2009-04-01 | Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) | Composicion farmaceutica para inhibir la apoptosis. |
ES2293834B1 (es) * | 2006-07-20 | 2009-02-16 | Consejo Superior Investig. Cientificas | Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. |
-
2010
- 2010-07-29 NZ NZ598125A patent/NZ598125A/en not_active IP Right Cessation
- 2010-07-29 CN CN201080043254.1A patent/CN102574818B/zh active Active
- 2010-07-29 AU AU2010277505A patent/AU2010277505B2/en not_active Ceased
- 2010-07-29 IN IN1378DEN2012 patent/IN2012DN01378A/en unknown
- 2010-07-29 EP EP10803937.1A patent/EP2460798B1/en active Active
- 2010-07-29 KR KR1020127005131A patent/KR101786761B1/ko active IP Right Grant
- 2010-07-29 MX MX2012001339A patent/MX2012001339A/es active IP Right Grant
- 2010-07-29 ES ES10803937T patent/ES2727711T3/es active Active
- 2010-07-29 CA CA2769408A patent/CA2769408C/en active Active
- 2010-07-29 TR TR2019/07804T patent/TR201907804T4/tr unknown
- 2010-07-29 EA EA201270215A patent/EA021838B1/ru not_active IP Right Cessation
- 2010-07-29 US US13/387,240 patent/US9040701B2/en active Active
- 2010-07-29 JP JP2012522195A patent/JP5694320B2/ja active Active
- 2010-07-29 BR BR112012002134A patent/BR112012002134B8/pt not_active IP Right Cessation
- 2010-07-29 WO PCT/ES2010/000349 patent/WO2011012746A2/es active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN102574818B (zh) | 2015-02-25 |
MX2012001339A (es) | 2012-03-07 |
NZ598125A (en) | 2014-05-30 |
ES2727711T3 (es) | 2019-10-18 |
KR101786761B1 (ko) | 2017-10-18 |
WO2011012746A2 (es) | 2011-02-03 |
CA2769408A1 (en) | 2011-02-03 |
AU2010277505B2 (en) | 2016-01-14 |
AU2010277505A1 (en) | 2012-03-08 |
EA021838B1 (ru) | 2015-09-30 |
CN102574818A (zh) | 2012-07-11 |
CA2769408C (en) | 2017-09-05 |
BR112012002134A2 (pt) | 2016-05-31 |
WO2011012746A3 (es) | 2011-07-14 |
JP5694320B2 (ja) | 2015-04-01 |
EA201270215A1 (ru) | 2012-11-30 |
US20120122868A1 (en) | 2012-05-17 |
JP2013500314A (ja) | 2013-01-07 |
EP2460798A2 (en) | 2012-06-06 |
BR112012002134B1 (pt) | 2021-03-02 |
US9040701B2 (en) | 2015-05-26 |
IN2012DN01378A (tr) | 2015-06-05 |
EP2460798A4 (en) | 2013-02-27 |
EP2460798B1 (en) | 2019-02-27 |
KR20120052354A (ko) | 2012-05-23 |
BR112012002134B8 (pt) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201907804T4 (tr) | Apaf-1 inhibitör bileşikleri. | |
EA201300684A1 (ru) | Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1 | |
EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
NO20081636L (no) | FAP - inhibitorer | |
EA201201665A1 (ru) | Новые соединения | |
MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
EA201000098A1 (ru) | Производные хиназолинамида | |
MX2010006241A (es) | Derivados de aminotriazol como agonistas de alx. | |
EA200901212A1 (ru) | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний | |
MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
ECSP088358A (es) | Tratamiento y profilaxis de microangiopatías | |
EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
TNSN08178A1 (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
EA201170832A1 (ru) | Пуриновые соединения | |
EA200801997A1 (ru) | Новые соединения | |
EA200901473A1 (ru) | Внутривенные и пероральные лекарственные формы прямого и обратимого ингибитора p2y12 | |
UA107784C2 (en) | Inhibitor of melanin production | |
EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
DOP2011000134A (es) | Lactamas como inhibidores de beta secretasa | |
MX2012007582A (es) | Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida. | |
EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
EA201100872A1 (ru) | Производные хиназолинамида | |
MA33848B1 (fr) | Dérivés sulfonamides hétérocycliques |